Zura Bio (NASDAQ:ZURA) Stock Sees Unusually High Call Option Buying

Key Points

• Zura Bio saw unusually high call-option activity, with investors purchasing 2,355 calls—about 165% above its typical volume of 889.
• Analyst sentiment is generally positive: the stock has a consensus “Moderate Buy” rating and a $17 price target, supported by recent price-target increases to $20 and $22.
• ZURA shares rose 6.4% to $3.58, but remain near their one-year low of $3.25; institutional investors own approximately 61.14% of the company.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors purchased 2,355 call options on the company. This represents an increase of approximately 165% compared to the typical volume of 889 call options.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. William Blair assumed coverage on Zura Bio in a report on Wednesday, July 8th. They issued an "outperform" rating for the company. Guggenheim raised their price objective on Zura Bio from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Wedbush lifted their price objective on shares of Zura Bio from $15.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Wall Street Zen upgraded shares of Zura Bio from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Zura Bio in a research note on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.00.

Zura Bio Stock Up 6.4%

Shares of NASDAQ:ZURA traded up $0.21 during trading on Monday, hitting $3.58. 2,157,734 shares of the company traded hands, compared to its average volume of 1,336,920. The stock has a market capitalization of $342.59 million, a price-to-earnings ratio of -3.16 and a beta of 0.01. The business's fifty day moving average is $4.85 and its 200-day moving average is $4.90. Zura Bio has a one year low of $3.25 and a one year high of $7.44.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, analysts forecast that Zura Bio will post -0.81 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently added to or reduced their stakes in the stock. Montanova Capital LLC grew its position in shares of Zura Bio by 4.1% during the second quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock worth $55,714,000 after acquiring an additional 376,000 shares during the last quarter. Siren L.L.C. lifted its position in Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company's stock valued at $22,222,000 after purchasing an additional 2,434,866 shares during the last quarter. Commodore Capital LP acquired a new position in Zura Bio during the 1st quarter valued at about $19,338,000. Affinity Asset Advisors LLC boosted its stake in Zura Bio by 41.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company's stock valued at $15,258,000 after purchasing an additional 750,632 shares during the period. Finally, EcoR1 Capital LLC bought a new position in Zura Bio in the 1st quarter worth about $7,019,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company's research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio's lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.